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The spread of antibiotic resistance among Gram-negative bacteria is a serious clinical threat, and infections with these organ-
isms are a leading cause of mortality worldwide. Traditional novel drug development inevitably leads to the emergence of new
resistant strains, rendering the new drugs ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics repre-
sents an attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-negative bacteria.
Here, we investigated novicidin as a possible antibiotic enhancer. The actions of novicidin in combination with rifampin, ceftri-
axone, or ceftazidime were investigated against 94 antibiotic-resistant clinical Gram-negative isolates and 7 strains expressing
NewDelhi metallo--lactamase-1. Using the checkerboard method, novicidin combined with rifampin showed synergy with
>70% of the strains, reducing theMICs significantly. The combination of novicidin with ceftriaxone or ceftazidime was syner-
gistic against 89.7% of the ceftriaxone-resistant strains and 94.1% of the ceftazidime-resistant strains. Synergistic interactions
were confirmed using time-kill studies with multiple strains. Furthermore, novicidin increased the postantibiotic effect when
combined with rifampin or ceftriaxone. Membrane depolarization assays revealed that novicidin alters the cytoplasmic mem-
brane potential of Gram-negative bacteria. In vitro toxicology tests showed novicidin to have low hemolytic activity and no det-
rimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the therapeutic potencies of ceftriaxone or
ceftazidime against resistant Gram-negative bacteria in vitro. In addition, novicidin boosted the activity of rifampin. This strat-
egy can have major clinical implications in our fight against antibiotic-resistant bacterial infections.
Bacterial infections remain one of the leading causes of deathworldwide. The ever-escalating problem of antibiotic resis-
tance leads to the redundancy of many antibiotics, resulting in
increased morbidity and mortality in both developed and devel-
oping countries. In particular, the effectiveness of antimicrobial
agents against Gram-negative pathogens, for example, Enterobac-
teriaceae, are being compromised at an alarming rate (1).
Bacteria in the Enterobacteriaceae family cause an arsenal of
serious infections, including pneumonia, wound infections, men-
ingitis, urinary tract infections, intra-abdominal infections (1),
and nosocomial bacteremia (2). Extended-spectrum -lactamase
(ESBL)-producing strains now predominate in many areas, con-
ferring resistance to cephalosporins and remaining sensitive only
to carbapenems and the older, more toxic polymyxin antibiotics
such as colistin (3). Furthermore, since 2007, infections with New
Delhi metallo--lactamase 1 (NDM-1)-producing “superbugs’”
have emerged. For these infections, virtually all antibiotics, in-
cluding carbapenems, are ineffective. Most NDM-1 strains are
usually susceptible only to “last line” drugs such as colistin, which
exhibits nephro- and neurotoxicity (4), and the bacteriostatic gly-
cylcycline tigecycline (5). The most optimal strategy to overcome
resistant infections is to use novel antimicrobial agents. However,
the traditional strategy of antibiotic discovery cannot maintain
pace with the high rate of resistance emergence and resistance
occurs just a few years after market release (6). In addition, the
discovery of novel antibiotics is costly and arduous, which means
producing large numbers of antibiotic classes within a short pe-
riod of time is extremely challenging (7–9).
Reviving the potency of existing antibiotics by combining
them with novel agents is an extremely desirable strategy to tackle
resistance (10). Antimicrobial peptides, in particular those target-
ing the bacterial cell envelope, have been shown to synergize with
conventional antibiotics (11). The dual action of weakening of the
cell envelope and increasing permeability may allow the intracel-
lular antibiotic concentration to reach a lethal level, which is un-
achievable by the antibiotic alone. Furthermore, the use of multi-
ple agents in combination may reduce or retard the emergence of
resistance to the individual antimicrobial components (10, 12).
It has been suggested that novicidin, a novel 18-residue cat-
ionic antimicrobial peptide, acts by inserting itself into the head
group region of the selectively targeted bacterial membrane bi-
layer. This subsequently causes membrane perturbation and tran-
sient pore formation and is bactericidal via the resulting leakage of
bacterial cell contents (13–15). Significant antimicrobial effects
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have been noted with several Gram-negative organisms, such as
Escherichia coli and Salmonella enterica (15). Novicidin was devel-
oped from ovispirin, which in turn originated from an ovine
cathelicidin known as sheep myeloid antimicrobial peptide 29
(SMAP-29) (13). This allowed for the construction of a peptide
more suitable for use as a therapeutic agent (14).
In this study, we aimed to investigate the effects of novicidin in
combination with conventional antibiotics, namely, rifampin and
the extended-spectrum cephalosporins, ceftriaxone and ceftazi-
dime, against 101 Gram-negative strains, including resistant E.
coli and bacteria in the Klebsiella-Enterobacter-Serratia (KES)
group. In addition, investigations were carried out to determine
the mechanism of action, hemolytic activity, and cytotoxicity of
novicidin.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used were
94 antibiotic-resistant Gram-negative clinical isolates, including 61 E. coli
and 33 isolates in the KES group from St George’s Hospital, London,
England. In addition, 7 strains with the blaNDM-harboring plasmid were
used: ATCC BAA-2468, BAA-2469, BAA-2470, BAA-2471, BAA-2472,
and BAA-2473 and NCTC 13443. Strain ATCC BAA-2468 is identified as
Enterobacter cloacae, strains ATCC BAA-2469 and BAA-2471 are identi-
fied as E. coli, and strains ATCC BAA-2470, BAA-2472, BAA-2473 and
NCTC 13443 are identified as Klebsiella pneumoniae. Bacterial strains
were grown in nutrient broth no. 2 (Oxoid, United Kingdom) and on
tryptone soya agar plates (Oxoid). The antibiotics used were as follows:
rifampin (Sanofi), ceftriaxone (Stravencon), ceftazidime (Wockhardt),
cefixime (Suprax), and cefotaxime (Reig Jofre). Antibiotics were prepared
in water or the provided solvent to an appropriate concentration. Novi-
cidin was kindly provided by Novozymes A/S, Denmark.
In vitro susceptibility to novicidin and antibiotics. The MICs of
novicidin, rifampin, ceftriaxone, ceftazidime, cefixime, and cefotaxime
for the 101 strains were calculated by using the broth microdilution
method. The MIC for each agent was identified as the lowest concentra-
tion required to inhibit bacterial growth. The MIC50 and MIC90 values
were calculated as the lowest concentrations required to inhibit growth in
50 and 90% of the strains, respectively.
Checkerboard assays to measure combination effects of novicidin
and antibiotics. The checkerboard assay method was used for the mea-
surement of combination effects of novicidin with the antibiotics. Com-
binations of two drugs were prepared in 96-well plates (Fisher Scientific
UK) using drug concentrations starting from 2-fold higher than their
MIC values and then serially diluted in a 2-fold manner. After the addition
of a log-phase bacterial inoculum of 1  105 to 5  105 CFU/ml, plates
were incubated at 37°C for 24 h and then read using an ELx800 absorbance
microplate reader (Bio-Tek). The effects of the combinations were exam-
ined by calculating the fractional inhibitory concentration index (FICI) of
each combination as follows: [(MIC of drug A, tested in combination)/
(MIC of drug A, tested alone)]  [(MIC of drug B, tested in combina-
tion)/(MIC of drug B, tested alone)]. The profile of the combination was
defined as synergistic if the FICI was0.5, indifferent if the FICI was0.5
but4.0 and antagonistic if the FICI was4 (16).
Time-kill curves of antibiotics alone and in combinationwith novi-
cidin. Twofold serial drug dilutions were prepared, added to a 96-well
plate alone and in combination, and incubated at 37°C with a log-phase
bacterial inoculum of 1 107 to 5 107 CFU/ml. After 0, 1, 2, 4, 7, and 24
h of incubation, viability expressed as CFU/ml was determined by plating
100 l of serial dilutions onto tryptone soy agar (Oxoid) plates, followed
by incubation at 37°C for 24 h. The colonies were counted using an
aCOLyte colony counter (Synbiosis) and analyzed using the accompany-
ing software. Synergistic activity was defined as a 2-log10 decrease in
CFU counts at 24 h of the combination compared to the most effective
single agent, in addition to a 2-log10 decrease compared to the 0-h
count. Indifference was defined as a1-log10 change in CFU counts, and
antagonism was defined as a 2-log10 increase in CFU at 24 h, of the
combination compared to the most effective single agent (17).
Measurement of bacterial cytoplasmic membrane potential. The
permeability of the bacterial cytoplasmic membrane after drug treatment
was assessed using a fluorescence assay as previously described (18, 19).
Log-phase cultures were washed twice and resuspended in a rejuvenating
buffer (5 mM HEPES [pH 7.2], 20 mM glucose) to an optical density
(OD) at 600 nm of 0.05. Membrane potential sensitive dye DiSC3 (3=3-
dipropylthiadicarbocyanine iodide; Sigma) (5) was added to the resus-
pended cells to a final concentration of 0.4 M, followed by incubation
until a stable reduction in fluorescence was achieved as a result of DiSC3
(5) uptake and cell quenching due to an intact membrane. Then, 100 mM
KCl was added to equilibrate the K ion concentration intra- and extra-
cellularly. The bacterial cell suspension was added to a 96-well microtiter
plate, followed by the addition of drugs in triplicate. Fluorescence was
measured by using a GloMax-Multimicroplate reader (Promega) at an
excitation wavelength of 622 nm and an emission wavelength of 670 nm.
Any drug-induced disruption of the cytoplasmic membrane resulted in an
increase in measurable florescence.
PAE of antibiotics alone and in combination with novicidin. Bacte-
ria were cultured overnight at 37°C in nutrient broth. One milliliter of the
culture was transferred to fresh nutrient broth medium containing single
or combinatory drugs. For the single drugs, concentrations 2, 5, or 10-fold
higher than MIC values of the drug were utilized. For the combinations,
concentrations 5-fold higher than the minimal enhancement concentra-
tions of both drugs were selected according to the checkerboard results.
After 1 h of drug exposure, the cultures were washed three times to remove
the antimicrobial agents. The bacterial cells were resuspended into nutri-
ent broth and grown at 37°C with continuous shaking at 100 rpm. Bacte-
rial viability was determined by CFU counting at 0, 1, 2, 3, 4, 6, and 8 h.
The postantibiotic effect (PAE) was calculated as follows: PAE T C,
where T is the time taken for drug exposed culture to increase by 1-log
CFU counts, and C is the time taken for control culture to increase by
1-log CFU counts (20).
Ex vivo hemolysis assay. A venous blood sample from a male human
donor was collected shortly before testing. Aliquots (10 l) of the hepa-
rinized blood were added to 0.5 ml of saline solution (0.9% NaCl) con-
taining different concentrations of novicidin in triplicate. After 1 h of
incubation at 37°C, the mixtures were centrifuged for 5 min at 5,000 g
to sediment the intact cells. The supernatants were isolated, and the absor-
bance values were measured at a wavelength of 545 nm. Hemolysis of novi-
cidin was analyzed against negative (0% lysis) and positive controls (100%
lysis) to calculate the percentage of hemolyzed cells, using the formulae as
follows: hemolysis  (ODtest  ODnegative control)/(ODpositive control 
ODnegative control) 100. An ethics approval (H-D-2007-0055) was obtained
from Danish National Committee on Health Research Ethics for using
human blood.
Assessment of cytotoxicity using neutral red uptake assay.To assess
the effects of cytotoxicity of novicidin, the L929 mouse fibroblast cell
line was utilized. Cells were grown in Eagle minimum essential me-
dium with 10% fetal bovine serum to 80% confluence. Adherent cells
were harvested and seeded at a concentration 5 105 cells per well into
a 96-well microtiter plate, which was incubated for 24 h at 37°C. Dif-
ferent concentrations of novicidin were added to the cells, followed by
incubation at 37°C for 24 and 72 h. Neutral red (25 mg/liter) was added
posttreatment for 3 h at 37°C and removed by washing the cells twice
with phosphate-buffered saline containing CaCl2/MgCl2. Intracellular
neutral red was extracted using neutral red removal solution (50%
ethanol, 1% acetic acid, and 49% water) for 15 min. Neutral red uptake
was measured at 540 nm, and cell viability was determined as a per-
centage of the untreated control. Sodium dodecyl sulfate (SDS) was
used as a positive control.
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RESULTS
In vitro susceptibility to novicidin and the antibiotics. The
MICs for novicidin, rifampin, ceftriaxone, ceftazidime, cefixime,
and cefotaxime were assessed for the 94 Gram-negative clinical
isolates and 7 NDM-1 strains. As shown in Table 1, the MIC for
novicidin for the 101 strains ranged from 1 to 8 mg/liter with an
MIC50 and MIC90 at 2 and 4 mg/liter, respectively. The MIC for
rifampin varied between 4 and 1,024 mg/liter. The MIC50 and
MIC90 were 16 and 32 mg/liter, respectively. The MIC for ceftri-
axone, ceftazidime, cefixime and cefotaxime ranged between
0.03125 and 2,048 mg/liter. The MIC50 and MIC90 were 1,024 and
2,048 mg/liter for ceftriaxone, 256 and 2,048 mg/liter for cefixime,
128 and 1,024 mg/liter for ceftazidime, and 512 and 2,048 mg/liter
for cefotaxime, respectively.
Checkerboard analysis of combination effects.The combina-
tion effects of novicidin combined with rifampin, ceftriaxone, and
ceftazidime were determined using the broth microdilution
checkerboard assay against 94 clinical isolates and 7 NDM-1
strains. The FIC indices for the combinations are shown in Table
2. The combination of novicidin with rifampin was shown to have
synergistic activity with70% of both E. coli and isolates in KES
group, with FIC indices between 0.018 and 0.5. In addition, the
combination was shown to have synergistic effects with all 7
NDM-1 strains. Novicidin reduced the MIC of rifampin between
2- and 512-fold, with the majority of strains exhibiting 4- or 8-fold
reductions in MIC values (see Tables S1, S2, and S3 in the supple-
mental material). Novicidin combined with ceftriaxone showed
synergy with 57.4% of the E. coli strains and 69.7% of isolates in
KES group. The combination of novicidin with ceftazidime pre-
sented synergy with 63.9% of the E. coli strains and 78.8% of iso-
lates in KES group. The FIC indices for the NDM-1 strains were
unable to be determined since the MICs for ceftriaxone and cef-
tazidime were higher than the maximum achievable checkerboard
concentration of 2,048 mg/liter. As shown in Table 3, synergistic
activities were demonstrated in the majority (89.7%) of the ceftri-
axone-resistant strains compared to a minority of the ceftriaxone-
sensitive strains (16.7%). A similar pattern was observed with the
novicidin and ceftazidime combination, whereby synergy was
seen in 94.1% of resistant strains compared to 3.8% of sensitive
strains. Novicidin reduced the MIC of ceftriaxone or ceftazidime
from 2- to2,048-fold (see Tables S1 and S2 in the supplemental
material).
Time-kill assays confirmed synergy of novicidin combined
with rifampin, ceftriaxone, or ceftazidime.Time-kill assays were
performed to examine the activities of novicidin in combination
with rifampin, ceftriaxone, and ceftazidime against five strains of
E. coli and KES group clinical strains, which represented an FICI of
	0.5 for each drug combination. The combination of rifampin
and novicidin was also tested against the seven NDM-1 strains. A
range of different concentrations was tested according to check-
erboard analysis, and the most effective and synergistic activities
are shown. As shown in Fig. 1, rifampin at 2 mg/liter (Fig. 1A and
B) and at 256 mg/liter (Fig. 1C and D) failed to reduce the viability
of the clinical isolate and the NDM-1 E. coli, and novicidin at 1 or
0.5 mg/liter (Fig. 1A and B) and at 4 or 2 mg/liter (Fig. 1C and D)
showed an initial killing of the bacteria, but regrowth was seen.
However, when rifampin at 2 mg/liter was combined with novici-
din at 1 (Fig. 1A) or 0.5 (Fig. 1B) mg/liter, 100% killing of the E.
coli cells was achieved at 2 and 4 h posttreatment, respectively.
Similarly, when rifampin at 256 mg/liter was combined with novi-
cidin at 4 (Fig. 1C) and 2 (Fig. 1D) mg/liter, complete killing of the
NDM-1 E. coli was achieved at 4 and 7 h posttreatment, respec-
tively. There were significant differences in the reduction of CFU
counts between the combination of novicidin with rifampin and
each of the single-drug (rifampin or novicidin) treatments
(P	 0.0001).
Novicidin and ceftriaxone combinations were tested against
ceftriaxone-resistant E. coli and KES group clinical isolates. As
seen in Fig. 1E, F, G, and H, ceftriaxone at 2,048 mg/liter was
unable to reduce the CFU counts of both strains. However, when
novicidin was added in the culture at 1 or 0.5 mg/liter and at 2 or
1 mg/liter, the bacterial cells were rapidly killed, showing 100%
reduction in the CFU count at 2 or 4 h posttreatment for the E. coli
TABLE 1 MIC values for novicidin and antibiotics used in this study
Antibiotic
MIC (mg/liter)
Range MIC50 MIC90
Novicidin 1 to 8 2 4
Rifampin 4 to1,024 16 32
Ceftriaxone 0.03125 to2,048 1,024 2,048
Cefixime 0.03125 to2,048 256 2,048
Ceftazidime 0.03125 to2,048 128 1,024
Cefotaxime 0.03125 to2,048 512 2,048
TABLE 2 Combination activity of novicidin with rifampin, ceftriaxone, and ceftazidime against the 101 Gram-negative Enterobacteriaceae strains
Strain or
isolate type Combination activity FICI
Total no. (%) of strains with activity when novicidin was
combined with
Rifampin Ceftriaxone Ceftazidime
E. coli strains Synergy 0.5 43 (70.5) 35 (57.4) 39 (63.9)
Indifferent 0.5,	4 18 (29.5) 26 (42.6) 22 (36.1)
Antagonism 4 0 0 0
KES isolates Synergy 0.5 28 (84.8) 23 (69.7) 26 (78.8)
Indifferent 0.5,	4 5 (15.2) 10 (30.3) 7 (21.2)
Antagonism 4 0 0 0
NDM-1 strains Synergy 0.5 7 (100)
Indifferent 0.5,	4 0
Antagonism 4 0
Novicidin Enhancement
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isolate, respectively (Fig. 1E and F), and at 1 or 2 h posttreatment
for the KES group strain (Fig. 1G and H), respectively, demon-
strating significant synergy. There were significant differences in
the reduction of CFU counts between combination of novicidin
with ceftriaxone and each of the single drug (ceftriaxone or novi-
cidin) treatments (P	 0.0001). The ability of novicidin enhance-
ment to rifampin or ceftriaxone was also compared to another
defensin, plectasin which was neither bactericidal on its own nor
did it boost the activity of rifampin (Fig. 1I) or ceftriaxone (Fig. 1J)
against Gram-negative bacteria to validate the assay. Similar pat-
terns of combination activities were observed for the strains tested
when novicidin was combined with ceftazidime (data not shown).
Membrane-permeabilizing effects of novicidin against E.
coli and KES group isolates. The effects of novicidin at the cyto-
plasmic bacterial membrane with both E. coli and an isolate from
the KES group were investigated with fluorescence assays. Imme-
diately after novicidin exposure, a sharp concentration-depen-
dent increase in fluorescence occurred with the E. coli strain (Fig.
2), indicating disruption of the bacterial membrane which led to
the leakage of the fluorescent dye. A similar effect was observed
when novicidin was used to treat the strain in the KES group
despite only high concentrations of novicidin, such as 64 and 32
mg/liter, resulting in an increase in fluorescence (data not shown).
Postantibiotic effect of novicidin alone and novicidin-anti-
biotic combinations. The PAEs of novicidin, rifampin, or ceftri-
axone singly and in combinations were determined; rifampin was
used at 5-fold higher than the MIC level and ceftriaxone at 10-fold
higher than the MIC level. Since novicidin was rapidly bactericidal
at a level 5-fold higher than its MIC, an MIC level that was 2-fold
higher was used to induce the PAE. Due to their enhanced syner-
gistic activities, the same concentrations for novicidin and rifam-
pin or ceftriaxone used singly for PAE induction would com-
pletely kill all of the bacterial cells within 1 h if combined.
Therefore, to induce PAEs with combination treatment, levels
5-fold higher than the minimal enhancement concentrations for
novicidin and rifampin or ceftriaxone were used and chosen from
the checkerboard results. As shown in Fig. 3A, the PAEs of both
novicidin and rifampin were estimated at 52.8 min for the E. coli
strain. The novicidin and rifampin combination doubled the PAE
to 121.8 min despite substantially lower concentrations being
used (P	 0.0001). As shown in Fig. 3B, the PAE of novicidin was
84 min, and ceftriaxone produced no PAE. The novicidin and
ceftriaxone combination exhibited a prolonged PAE of 117 min
(P	 0.0001).
Hemolytic effects of novicidin. Hemolysis due to novicidin
was tested using human blood. As shown in Table 4, at the lowest
tested novicidin concentration of 125 mg/liter, hemolysis oc-
curred at a rate of 4.4% and it ranged up to 19.9% at the highest
tested concentration of 1,000 mg/liter. A 50% hemolytic concen-
tration could not be accurately predicted due to the nonlinear
correlation with novicidin concentration; hemolysis, however, is
shown to occur at 1,000 mg/liter based on the current data.
Extrapolation provides an estimate of between 2,500 and 3,000
mg/liter. One-hundred percent hemolysis was seen when the
blood was added into distilled water (Table 4). The experiments
were repeated twice with reproducible results.
Determination of cytotoxicity by neutral red uptake. To as-
sess the cytotoxicity of novicidin, neutral red uptake was mea-
sured after treatment of the murine fibroblasts with different con-
centrations of novicidin. As seen in Table 5, cell viability was well
conserved and remained between 93 to 99% after 24 h of novicidin
exposure, and 98 to 102% after 72 h of exposure for all tested
concentrations. This indicates low levels of general cytotoxicity
even with prolonged exposure. SDS was used as a positive control:
concentrations of 80, 100, and 120 mg/liter reduced cell viability
to 80, 9, and 0% at 24 h and 55, 0, and 0% at 72 h, respectively,
confirming the validity of the assay. These experiments were re-
peated twice with reproducible results.
DISCUSSION
Novicidin is a newly derived antimicrobial peptide. In this study,
we demonstrated for the first time that novicidin synergized with
rifampin and extended-spectrum cephalosporins (ceftriaxone
and ceftazidime) against Gram-negative antibiotic-resistant bac-
terial strains in vitro. The 94 clinical isolates from the Enterobac-
teriaceae family covered a broad host distribution in the South
London area, and the 7 NDM-1 strains represented the most re-
sistant type of Gram-negative bacteria. Most of the ceftriaxone
and ceftazidime resistant bacteria were also resistant to cefotaxime
and cefixime, indicating that these were ESBL-producing strains.
Rifampin is an important component of the combination reg-
imen used for the treatment of tuberculosis and many Gram-
positive bacterial infections (21). Rifampin is not considered to be
standard treatment for Enterobacteriaceae infections, and thus a
breakpoint for resistance is not available. Our results showed that
the MIC50 and MIC90 for rifampin were 16 and 32 mg/liter, re-
spectively. Recently, rifampin has been introduced in combina-
tion therapy for the treatment of infections caused by multidrug
resistant Gram-negative bacteria (22, 23). Our checkerboard anal-
ysis revealed that the combination of novicidin and rifampin
showed synergistic effects with 70% of the tested strains with
marginally higher effectiveness with the bacterial strains in KES
group compared to E. coli. Novicidin was able to revive the activity
of rifampin by reduction of rifampin MIC by 2- to 512-fold. The
combination was also synergistic with all of the strains harboring
NDM-1 plasmids. Synergistic activity of novicidin with rifampin
was confirmed using time-kill assays, a method allowing for a
more dynamic analysis of bactericidal and combinatorial effects.
Time-kill assays were performed with multiple strains, repeatedly
demonstrating that at concentrations at which both novicidin and
TABLE 3 Combination activity of novicidin with ceftriaxone and ceftazidime against the 94 Gram-negative clinical isolates
Strain type (no. of strains)
Total no. (%) of strains with activity when novicidin was combined with ceftriaxone and ceftazidime
Synergy (FICI 0.5) Indifferent (FICI 0.5 and	 4) Antagonism (FICI 4)
Ceftriaxone-resistant strains (58) 52 (89.7) 6 (10.3) 0
Ceftriaxone-sensitive strains (36) 6 (16.7) 30 (83.3) 0
Ceftazidime-resistant strains (68) 64 (94.1) 4 (5.9) 0
Ceftazidime-sensitive strains (26) 1 (3.8) 25 (96.2) 0
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FIG 1 Time-kill analysis showing the effects of novicidin in combination with rifampin and ceftriaxone against antibiotic-resistant E. coli strains. The peptide
and antibiotics alone, or each combined with novicidin, were added to the bacterial cultures, and CFU counts were carried out at different time points. (A and
B) Combination of rifampin at 2 mg/liter and novicidin at 1 mg/liter (A) or 0.5 mg/liter (B) against a clinical isolate of E. coli. (C and D) Combination of rifampin
at 256 mg/liter and novicidin at 4 mg/liter (C) or 2 mg/liter (D) against an NDM-1 E. coli strain. (E and F) Combination of ceftriaxone at 2,048 mg/liter and
novicidin at 1 mg/liter (E) or 0.5 mg/liter (F) against a clinical isolate of E. coli. (G and H) Combination of ceftriaxone at 2,048 mg/liter and novicidin at 2 mg/liter
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rifampin were ineffective alone, in combination, rapid bacteri-
cidal activities were seen with 100% elimination of the bacterial
cells within a few hours of drug exposure, which substantially
decreased the treatment duration. Rifampin alone required higher
concentrations such as 128 mg/liter to completely eradicate E. coli
cells in culture (data not shown), and this concentration was only
able to reduce the CFU counts of a KES group strain by 2 logs (data
not shown). However, when combined with novicidin at 0.5 or 1
mg/liter, rifampin at concentrations of just 2 mg/liter killed 100%
of the bacterial cells at 4 or 2 h posttreatment (Fig. 1A and B). The
combination was also able to enhance the activities of rifampin
against NDM-1 strains (Fig. 1C and D); however, high rifampin
concentrations were required.
Novicidin also enhanced the activities of ceftriaxone and cef-
tazidime. Interestingly, the majority of synergy was observed with
strains showing resistance to ceftriaxone or ceftazidime. This was
also confirmed with time-kill assays testing multiple strains.
Ceftriaxone has a long half-life and is used to treat septicemia,
pneumonia, meningitis, and urinary tract infections. Clinical
pharmacokinetic data revealed that after a single intravenous in-
jection of a standard 2,000-mg dose the plasma Cmax was 
257
mg/liter, and at 24 h postadministration the plasma concentration
was
15 mg/liter. However, in urine, the Cmax of the ceftriaxone
was 
2,692 mg/liter within 2 h after intravenous administration
of 2,000 mg (24). Ceftazidime, like ceftriaxone, has broad-spec-
trum activity and is one of the few agents in this class to be used
clinically against Pseudomonas spp. Ceftazidime pharmacokinetic
data show comparative serum Cmax, since a 1,000-mg intravenous
dose produced a peak concentration of
140 mg/liter. Similarly,
much higher concentrations are present in the urine. At up to 6 h
postinfusion of a 50-mg/kg dose of ceftazidime, the concentration
in collected urine samples ranged from 2,370 to 11,340 mg/liter,
with ca. 75% of the drug being recovered unchanged (25). Based
on these data, it may be argued that novicidin-cephalosporin
combinations may not be clinically appropriate for the treatment
of septicemia since 2,048 mg/liter appears to be an unattainable
serum concentration. However, pharmacokinetic analysis of
novicidin in combination with the antibiotics may give more re-
alistic estimations of the concentrations required to achieve syn-
ergistic and bactericidal effects. Nevertheless, the extremely high
concentrations of both ceftriaxone and ceftazidime in the urine
(G) or 1 mg/liter (H) against a clinical isolate of the KES group. (I and J) Negative controls were a combination of plectasin at 32 mg/liter with rifampin at 256
mg/liter against an NDM-1 E. coli isolate (I) and a combination of plectasin at 32 mg/liter with ceftriaxone at 2,048 mg/liter against a clinical isolate of the KES
group (J). These results are means and standard deviations (SD) from two independent experiments.
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FIG 2 Determination of cytoplasmic membrane potential changes by novici-
din against a clinical isolate of E. coli. A log-phase E. coli culture was incubated
with DiSC3 (5) to a final concentration of 0.4 M until no more quenching
was detected, which was followed by the addition of 0.1 M KCl. Novicidin was
incubated with the cultures at different concentrations. The changes in fluo-
rescence were monitored at various time points. The data are means and SD
from two independent experiments.
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FIG 3 Induction of rifampin (A) and ceftriaxone (B) PAEs by novicidin
against a clinical isolate of E. coli. The concentrations used for single-drug PAE
induction were rifampin at 80 mg/liter, novicidin at 2 mg/liter, and ceftriaxone
at 1,024 mg/liter. For combination PAE induction, rifampin at 20 mg/liter plus
novicidin at 0.625 mg/liter or ceftriaxone at 640 mg/liter plus novicidin at
0.625 mg/liter were used. The data are means and SD from two independent
experiments.
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indicate that either of these agents in combination with novicidin
may be clinically applicable in treating urinary tract infections.
The combination of novicidin with rifampin or ceftriaxone
was able to suppress bacterial growth against our tested bacterial
strains after the drugs had been removed. Interestingly, although
ceftriaxone alone was unable to produce a PAE (26), a prolonged
PAE was generated in the combination with novicidin. Therefore,
novicidin and the antibiotic combinations, possibly by prolonging
the PAE, are able to reduce the likelihood of resistance develop-
ment. A longer PAE also contributes a therapeutic advantage in
devising dosing intervals for drug regimens. Generally, a longer
PAE enables less frequent drug doses while maintaining therapeu-
tic efficacy; this can reduce adverse effects and increase patient
compliance (20).
The precise mechanism underlying the antibiotic enhancing
activities of novicidin is unclear. Due to decreased cell envelope
permeability and altered efflux pump systems, Gram-negative
bacteria are intrinsically resistant to many antibiotics, such as ri-
fampin. Rifampin inhibits bacterial DNA-dependent RNA poly-
merase (23), and its action on bacterial cells is concentration de-
pendent. It has been shown that compounds that target the cell
wall or cell membrane were found to potentiate the activities of
other antibiotics (11, 18, 27, 28). Previous work on artificial mem-
branes showed that low concentrations of novicidin result in tran-
sient pore formation and increased concentrations cause cell
membrane disruption (13, 29). It has also been suggested that
novicidin accumulates on the membrane surface until a deter-
gent-like disintegration occurs (known as the carpet mechanism)
(13). Consistent with this finding, we showed that novicidin dis-
turbed the cytoplasmic membrane potential by depolarizing the
membrane, and even at very low concentrations, significant fluo-
rescence release was observed. It is likely that the enhanced activ-
ities of rifampin with novicidin were due to increased cell mem-
brane permeability against the Gram-negative bacteria, leading to
higher intracellular accumulations of rifampin (30, 31).
Cephalosporins are -lactam antibiotics and interact with
transpeptidases, which are also known as penicillin-binding pro-
teins (32), blocking the terminal step in bacterial cell wall biosyn-
thesis (33). Accordingly, the synergy between novicidin and ceftri-
axone or ceftazidime may be attributed to a “double hit”
mechanism: (i) the disruption of the membrane by novicidin and
(ii) the inhibition of cell well biosynthesis by ceftriaxone or cefta-
zidime, which may be sufficient in reducing the integrity of the cell
envelope, resulting in cell death. Our checkerboard analysis
showed that synergy was more likely with ceftriaxone- or ceftazi-
dime-resistant strains, and resistance to such agents is usually due
to the acquisition of plasmids carrying ESBL genes, producing
enzymes which hydrolyze the -lactam ring of antibiotics. It is
unclear how novicidin enhances the activities of these cephalospo-
rins against resistant strains. We hypothesized that the enhanced
antibiotic activities were likely due to the action of pore formation
by novicidin, leading to the elimination of enzymes or plasmids,
the resistance determinants. However, this notion needs to be
further tested.
The findings from our study demonstrate proof of concept,
displaying the potential of peptide-antibiotic combinations which
undoubtedly contribute to important clinical applications. First,
our demonstration of novicidin as a powerful antibiotic enhancer
strongly illustrates that other similar peptides or compounds may
potentially be beneficial above and beyond their direct antimicro-
bial properties. Second, the addition of novicidin reduced MICs
and improved the rate of bactericidal activities of antibiotics;
therefore, highly resistant Gram-negative bacteria which are ex-
tremely difficult to kill can be eliminated from the bacterial cul-
ture. Finally, novicidin exhibited a very low hemolytic activity, a
finding which was in agreement with those of Dorosz et al. (14). In
addition, novicidin was nontoxic, and cell viability was well con-
served after treatment with different concentrations of novicidin.
Combination therapy with novicidin shows promise for becom-
ing a novel and much clinically desired therapeutic option to treat
“superbug” infections. In vivo work is under way aiming to expose
the therapeutic potential of novicidin in combination regimens to
treat infections caused by antibiotic-resistant Gram-negative bac-
teria.
ACKNOWLEDGMENTS
This study was funded with support from the European Commission
under grant agreement 278998 (BacAttack).
This communication reflects the views only of its authors, and the
Commission cannot be held responsible for any use which may be made of
the information contained here.
We thank Julie Johnson from St George’s Healthcare NHS Trust for
kindly providing the clinical strains and Novozymes A/S Denmark for
providing novicidin.
REFERENCES
1. Paterson DL. 2006. Resistance in gram-negative bacteria: Enterobacteria-
ceae. Am J Infect Control 34:S20 –S28. http://dx.doi.org/10.1016/j.ajic
.2006.05.238.
TABLE 4 Hemolytic effects of novicidin at different concentrations
Treatment groupa Hemolysis (%)
Novicidin concn (mg/liter)
125 4.4
250 7.7
500 13.2
750 13.3
1,000 19.9
Negative control 0
Positive control 100
a For the negative control, blood was mixed with saline solution. For the positive
control, blood was mixed with distilled water.
TABLE 5 Cell viability following treatment with novicidin assessed via
neutral red uptake
Novicidin or SDS concn (mg/liter)
Viability (%)
24 h 72 h
Novicidin
0 100 100
25 95 102
50 93 102
100 99 98
200 99 101
SDS
80 80 55
100 9 0
120 0 0
Novicidin Enhancement
October 2015 Volume 59 Number 10 aac.asm.org 6239Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 28, 2015 by UNIVERSITY O
F SO
UTHAM
PTO
N HIG
HFIELD
http://aac.asm
.org/
D
ow
nloaded from
 
2. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe
KW. 2005. Bloodstream infections caused by antibiotic-resistant gram-
negative bacilli: risk factors for mortality and impact of inappropriate
initial antimicrobial therapy on outcome. Antimicrob Agents Chemother
49:760 –766. http://dx.doi.org/10.1128/AAC.49.2.760-766.2005.
3. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-
producing Enterobacteriaceae: an emerging public health concern. Lancet
Infect Dis 8:159 –166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
4. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012.
Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti
Infect 10:917–934. http://dx.doi.org/10.1586/eri.12.78.
5. Nordmann P, Poirel L, Toleman MA, Walsh TR. 2011. Does broad-
spectrum beta-lactam resistance due to NDM-1 herald the end of the
antibiotic era for treatment of infections caused by Gram-negative bacte-
ria? J Antimicrob Chemother 66:689 – 692. http://dx.doi.org/10.1093/jac
/dkq520.
6. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. 2010. Challenges of
antibacterial discovery revisited. Ann N Y Acad Sci 1213:5–19. http://dx
.doi.org/10.1111/j.1749-6632.2010.05828.x.
7. Coates AR, Halls G, Hu Y. 2011. Novel classes of antibiotics or more of
the same? Br J Pharmacol 163:184 –194. http://dx.doi.org/10.1111/j.1476
-5381.2011.01250.x.
8. Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H.
2004. Antibacterial research and development in the 21st Century: an
industry perspective of the challenges. Curr Opin Microbiol 7:445– 450.
http://dx.doi.org/10.1016/j.mib.2004.08.009.
9. Livermore DM, British Society for Antimicrobial Chemotherapy Work-
ing Party. 2011. Discovery research: the scientific challenge of finding new
antibiotics. J Antimicrob Chemother 66:1941–1944. http://dx.doi.org/10
.1093/jac/dkr262.
10. Kalan L, Wright GD. 2011. Antibiotic adjuvants: multicomponent anti-
infective strategies. Expert Rev Mol Med 13:e5. http://dx.doi.org/10.1017
/S1462399410001766.
11. Hu Y, Liu A, Vaudrey J, Vaiciunaite B, Moigboi C, McTavish SM,
Kearns A, Coates A. 2015. Combinations of beta-lactam or aminoglyco-
side antibiotics with plectasin are synergistic against methicillin-sensitive
and methicillin-resistant Staphylococcus aureus. PLoS One 10:e0117664.
http://dx.doi.org/10.1371/journal.pone.0117664.
12. Soothill G, Hu Y, Coates A. 2013. Can we prevent antimicrobial resis-
tance by using antimicrobials better? Pathogens 2:422– 435. http://dx.doi
.org/10.3390/pathogens2020422.
13. Nielsen SB, Otzen DE. 2010. Impact of the antimicrobial peptide novi-
cidin on membrane structure and integrity. J Colloid Interface Sci 345:
248 –256. http://dx.doi.org/10.1016/j.jcis.2010.01.065.
14. Dorosz J, Gofman Y, Kolusheva S, Otzen D, Ben-Tal N, Nielsen NC,
Jelinek R. 2010. Membrane interactions of novicidin, a novel antimicro-
bial peptide: phosphatidylglycerol promotes bilayer insertion. J Phys
Chem B 114:11053–11060. http://dx.doi.org/10.1021/jp1052248.
15. Balakrishnan VS, Vad BS, Otzen DE. 2013. Novicidin’s membrane
permeabilizing activity is driven by membrane partitioning but not by
helicity: a biophysical study of the impact of lipid charge and chole-
sterol. Biochim Biophys Acta 1834:996 –1002. http://dx.doi.org/10.1016/j
.bbapap.2013.03.025.
16. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts
between them. J Antimicrob Chemother 52:1. http://dx.doi.org/10.1093
/jac/dkg301.
17. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of
three different in vitro methods of detecting synergy: time-kill, checker-
board, and E test. Antimicrob Agents Chemother 40:1914 –1918.
18. Hu Y, Coates AR. 2012. Enhancement by novel anti-methicillin-resistant
Staphylococcus aureus compound HT61 of the activity of neomycin, gen-
tamicin, mupirocin, and chlorhexidine: in vitro and in vivo studies.
J Antimicrob Chemother 68:374 –384. http://dx.doi.org/10.1093/jac
/dks384.
19. WuM,Hancock RE. 1999. Interaction of the cyclic antimicrobial cationic
peptide bactenecin with the outer and cytoplasmic membrane. J Biol
Chem 274:29 –35. http://dx.doi.org/10.1074/jbc.274.1.29.
20. Spivey JM. 1992. The postantibiotic effect. Clin Pharm 11:865– 875.
21. Rodriguez-Pardo D, Pigrau C, Corona PS, Almirante B. 2015. An
update on surgical and antimicrobial therapy for acute periprosthetic joint
infection: new challenges for the present and the future. Expert Rev
Anti-Infect Ther 13:249 –265. http://dx.doi.org/10.1586/14787210.2015
.999669.
22. Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M,
Vay C, Famiglietti A. 2014. Activity of the colistin-rifampicin combi-
nation against colistin-resistant, carbapenemase-producing Gram-
negative bacteria. J Chemother 26:211–216. http://dx.doi.org/10.1179
/1973947813Y.0000000136.
23. Drapeau CM, Grilli E, Petrosillo N. 2010. Rifampicin combined regi-
mens for gram-negative infections: data from the literature. Int J Antimi-
crob Agents 35:39 – 44. http://dx.doi.org/10.1016/j.ijantimicag.2009.08
.011.
24. Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J,
Kaplan SA. 1981. Pharmacokinetics of ceftriaxone in humans. Antimi-
crob Agents Chemother 20:634 – 641. http://dx.doi.org/10.1128/AAC.20
.5.634.
25. Leeder JS, Spino M, Tesoro AM, MacLeod SM. 1983. High-pressure
liquid chromatographic analysis of ceftazidime in serum and urine. J An-
timicrob Chemother 24:720 –724. http://dx.doi.org/10.1128/AAC.24.5
.720.
26. Burgess DS. 2005. Use of pharmacokinetics and pharmacodynamics to
optimize antimicrobial treatment of Pseudomonas aeruginosa infections.
Clin Infect Dis 40(Suppl 2):S99 –S104. http://dx.doi.org/10.1086/426189.
27. Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fortuna M,
Drenaggi D, Scalise G. 2000. In vitro activities of membrane-active pep-
tides alone and in combination with clinically used antimicrobial agents
against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:
1716 –1719. http://dx.doi.org/10.1128/AAC.44.6.1716-1719.2000.
28. Anantharaman A, Rizvi MS, Sahal D. 2010. Synergy with rifampin and
kanamycin enhances potency, kill kinetics, and selectivity of de novo-
designed antimicrobial peptides. Antimicrob Agents Chemother 54:1693–
1699. http://dx.doi.org/10.1128/AAC.01231-09.
29. Bertelsen K, Dorosz J, Hansen SK, Nielsen NC, Vosegaard T. 2012.
Mechanisms of peptide-induced pore formation in lipid bilayers investi-
gated by oriented 31P solid-state NMR spectroscopy. PLoS One 7:e47745.
http://dx.doi.org/10.1371/journal.pone.0047745.
30. Pages JM, Sandrine AF, Mahamoud A, Bolla JM, Davin-Regli A, Che-
valier J, Garnotel E. 2010. Efflux pumps of gram-negative bacteria, a new
target for new molecules. Curr Top Med Chem 10:1848 –1857. http://dx
.doi.org/10.2174/156802610793176620.
31. Zechini B, Versace I. 2009. Inhibitors of multidrug resistant efflux sys-
tems in bacteria. Recent Pat Anti infect Drug Discov 4:37–50. http://dx.doi
.org/10.2174/157489009787260061.
32. Barbas JA, Diaz J, Rodriguez-Tebar A, Vazquez D. 1986. Specific loca-
tion of penicillin-binding proteins within the cell envelope of Escherichia
coli. J Bacteriol 165:269 –275.
33. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of cef-
taroline and other beta-lactams for penicillin-binding proteins from
Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents
Chemother 54:1670 –1677. http://dx.doi.org/10.1128/AAC.00019-10.
Soren et al.
6240 aac.asm.org October 2015 Volume 59 Number 10Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 28, 2015 by UNIVERSITY O
F SO
UTHAM
PTO
N HIG
HFIELD
http://aac.asm
.org/
D
ow
nloaded from
 
